ARAP1 and liver dysplastic nodule: Such findings underscore the biomarker potential of ncRNAs in DN—e.g., circulating levels of certain lncRNAs (ARAP1-AS1/AS2) and circRNAs have been proposed as novel minimally invasive markers of early DN and its fibrotic progression [68], as well as their promise as therapeutic targets for slowing DN progression.